The CDK4/6 inhibitor revolution - a game-changing era for breast cancer treatment

Area of Science:

• Oncology
• Pharmacology
• Genetics

Background:

• Cyclin-dependent kinase (CDK) 4/6 inhibitors combined with endocrine therapy represent the standard of care for advanced hormone receptor-positive, HER2 non-amplified (HR +HER2 -) breast cancer.
• These therapies are also utilized as adjuvant treatment for early-stage breast cancer patients with elevated risk.
• The clinical efficacy of CDK4/6 inhibitors has introduced significant challenges, including managing acquired resistance, predicting treatment response, and optimizing drug sequencing and timing.

Purpose of the Study:

• To elucidate the rationale behind targeting CDK4/6 pathways in breast cancer.
• To present updated clinical evidence regarding CDK4/6 inhibitor efficacy and its implications for clinical practice.
• To discuss ongoing research aimed at overcoming challenges associated with the widespread use of these agents.

Main Methods:

• Review of current clinical evidence and established treatment guidelines for CDK4/6 inhibitors in breast cancer.
• Analysis of research investigating mechanisms of acquired resistance to CDK4/6 inhibitors.
• Exploration of predictive biomarkers for patient selection and therapeutic response.

Main Results:

• CDK4/6 inhibitors have demonstrated significant clinical benefit in HR +HER2 - advanced and high-risk early-stage breast cancer when used with endocrine therapy.
• Acquired resistance is a major clinical challenge, necessitating further research into alternative strategies and combination therapies.
• Identifying predictive biomarkers is crucial for optimizing patient selection and maximizing treatment benefit.

Conclusions:

• CDK4/6 inhibitors are integral to breast cancer treatment, but challenges related to resistance and patient selection persist.
• Continued research into novel therapeutic strategies, resistance mechanisms, and predictive biomarkers is essential for advancing patient care.
• Optimizing the timing and sequencing of CDK4/6 inhibitors within treatment paradigms will further enhance clinical outcomes.